Overview

Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients

Status:
Completed
Trial end date:
2019-01-08
Target enrollment:
Participant gender:
Summary
The purpose of this dose-escalation study is to assess the safety and tolerability of treatment with Chidamide in a range of doses combined with CHOP in fixed dose in patients with newly diagnosed peripheral T-cell lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
Chipscreen Biosciences, Ltd.
Treatments:
Cyclophosphamide
Doxorubicin
Liposomal doxorubicin
Prednisone
Vincristine